SNDX Q2 2017 Earnings — Syndax Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SNDXSyndax Pharmaceuticals, Inc.

$2B

Q2 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$305,000+0.0% YoY

Gross Profit

$305,000100.0% margin

Operating Income

-$14M-4538.4% margin

Net Income

-$14M-4471.8% margin

EPS (Diluted)

$-0.70

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$135M

Total Liabilities

$25M

Stockholders' Equity

$109M

Cash & Equivalents

$23M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$305,000	$305,000	+0.0%
Gross Profit	$305,000	$305,000	+0.0%
Operating Income	-$14M	-$9M	-60.3%
Net Income	-$14M	-$8M	-63.2%